UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 126

Sortiert nach

Weekly Volume and Dosimetric Changes During Chemoradiotherapy With Intensity-Modulated Radiation Therapy for Head and Neck Cancer: A Prospective Observational Study

International journal of radiation oncology, biology, physics, 2010-04, Vol.76 (5), p.1360-1368

2010

Volltextzugriff (PDF)

Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck

British journal of cancer, 2011-08, Vol.105 (5), p.618-627

2011

Volltextzugriff (PDF)

TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441)

Annals of oncology, 2019-07, Vol.30, p.iv26-iv26

2019

Volltextzugriff (PDF)

Vicia faba agglutinin, the lectin present in broad beans, stimulates differentiation of undifferentiated colon cancer cells

Gut, 1999-05, Vol.44 (5), p.709-714

1999

Volltextzugriff (PDF)

295 Proteomic and Circulating Free DNA Analysis Outcome Predictors in the GALAXY TrialTM (NCT01348126): a Randomized Phase IIB/III Study of Ganetespib (STA-9090) in Combination with Docetaxel Versus Docetaxel Alone in Subjects with Stage IIIb/IV NSCLC

European journal of cancer (1990), 2012-11, Vol.48, p.90-90

2012

Volltextzugriff (PDF)

Asparaginase encapsulated in erythrocytes as second‐line treatment in hypersensitive patients with acute lymphoblastic leukaemia

British journal of haematology, 2022-06, Vol.197 (6), p.745-754

2022

Volltextzugriff (PDF)

Expression of E-cadherin-associated molecules (alpha-, beta-, and gamma- catenins and p120) in colorectal polyps

The American journal of pathology, 1997-06, Vol.150 (6), p.1977-1984

1997

Volltextzugriff (PDF)

Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: Rationale for future randomised trials in human papilloma virus-negative disease

European journal of cancer (1990), 2013-05, Vol.49 (7), p.1609-1618

2013

Volltextzugriff (PDF)

A phase I, open-label study (EGF 100262) of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)

Radiotherapy and oncology, 2007, Vol.82, p.S30-S30

2007

Volltextzugriff (PDF)

The role of induction chemotherapy in the treatment of patients with locally advanced head and neck cancers: A review

The gulf journal of oncology, 2008-07 (4), p.8

2008

Volltextzugriff (PDF)

A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma

European journal of cancer (1990), 2001-07, Vol.37 (11), p.1352-1358

2001

Volltextzugriff (PDF)

1093 Low or undetectable levels of MPL (thrombopoietin receptor gene) mRNA expression on tumour cell lines and primary tumours compared with EPOR, ERBB2, and IGF1R

European journal of cancer supplements, 2009, Vol.7 (2), p.112-113

2009

Volltextzugriff (PDF)

A double blind randomized phase 2 PILOT study of ERYASPASE in patients with acute lymphoblastic leukemia/lymphoma

Annals of oncology, 2017-09, Vol.28, p.v369-v369

2017

Volltextzugriff (PDF)

Adhesion molecules: opportunities for modulation and a paradigm for novel therapeutic approaches in cancer

Expert opinion on investigational drugs, 1997-10, Vol.6 (10), p.1465-1478

1997

Volltextzugriff (PDF)

TRYbeCA-2: A randomized phase II/III study of eryaspase in combination with gemcitabine and carboplatin chemotherapy versus chemotherapy alone as first-line treatment in patients with metastatic or locally recurrent triple-negative breast cancer

Annals of oncology, 2019-10, Vol.30, p.v138

2019

Volltextzugriff (PDF)

381TiPTRYbeCA-2: A randomized phase II/III study of eryaspase in combination with gemcitabine and carboplatin chemotherapy versus chemotherapy alone as first-line treatment in patients with metastatic or locally recurrent triple-negative breast cancer

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

381TiP - TRYbeCA-2: A randomized phase II/III study of eryaspase in combination with gemcitabine and carboplatin chemotherapy versus chemotherapy alone as first-line treatment in patients with metastatic or locally recurrent triple-negative breast cancer

Annals of oncology, 2019-10, Vol.30, p.v138-v138

2019

Volltextzugriff (PDF)

P-098TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441)

Annals of oncology, 2019-07, Vol.30 (Supplement_4)

2019

Volltextzugriff (PDF)

P-80 TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma

Annals of oncology, 2020-07, Vol.31, p.S115

2020

Volltextzugriff (PDF)

201PEXPLORATORY ANALYSIS OF CIRCULATING FREE DNA TO IDENTIFY BIOMARKERS PREDICTIVE OF OUTCOME IN GALAXY-1, A LARGE RANDOMIZED PHASE IIB STUDY OF GANETESPIB IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL ALONE IN ADVANCED NSCLC (NCT01348126)

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv69-iv69

2014

Volltextzugriff (PDF)

Exploratory Analysis of Circulating Free Dna to Identify Biomarkers Predictive of Outcome in Galaxy-1, a Large Randomized Phase Iib Study of Ganetespib in Combination with Docetaxel Versus Docetaxel Alone in Advanced Nsclc (Nct01348126)

Annals of oncology, 2014-09, Vol.25, p.iv69

2014

Volltextzugriff (PDF)

Phosphorylation of beta-catenin and epidermal growth factor receptor by intestinal trefoil factor

Laboratory investigation, 1997-12, Vol.77 (6), p.557

1997

Volltextzugriff (PDF)

FGF‐1 and FGF‐2 regulate the expression of E‐cadherin and catenins in pancreatic adenocarcinoma

International journal of cancer, 2001-12, Vol.94 (5), p.652-661

2001

Volltextzugriff (PDF)

A Phase 2b of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180)

Annals of oncology, 2017-09, Vol.28, p.v211-v211

2017

Volltextzugriff (PDF)

Abstract PD5-3: Anti-metastatic activity, chemotherapeutic enhancement and therapeutic potential of targeting Hsp90 with ganetespib in triple negative breast cancer

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.PD5-3-PD5-3

2013

Volltextzugriff (PDF)

1 – 25 von 126

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(112)
Mit Volltextzugriff
(119)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(125)
Japanisch
(7)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(35)
Humans
(33)
Life Sciences & Biomedicine
(32)
Oncology
(28)
Female
(19)
Biological And Medical Sciences
(18)
Tumors
(18)
Medical Sciences
(17)
Male
(16)
Adult
(15)
Aged
(15)
Middle Aged
(15)
Hematology, Oncology And Palliative Medicine
(10)
Antineoplastic Agents - Therapeutic Use
(8)
Hsp90 Heat-Shock Proteins - Antagonists & Inhibitors
(7)
Immunohistochemistry
(7)
Quinazolines - Therapeutic Use
(7)
Treatment Outcome
(7)
Aged, 80 And Over
(6)
Animals
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Weekly Volume and Dosimetric Changes During Chemoradiotherapy With Intensity-Modulated Radiation Therapy for Head and Neck Cancer: A Prospective Observational Study

Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck

TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441)

Vicia faba agglutinin, the lectin present in broad beans, stimulates differentiation of undifferentiated colon cancer cells

295 Proteomic and Circulating Free DNA Analysis Outcome Predictors in the GALAXY TrialTM (NCT01348126): a Randomized Phase IIB/III Study of Ganetespib (STA-9090) in Combination with Docetaxel Versus Docetaxel Alone in Subjects with Stage IIIb/IV NSCLC

Asparaginase encapsulated in erythrocytes as second‐line treatment in hypersensitive patients with acute lymphoblastic leukaemia

Expression of E-cadherin-associated molecules (alpha-, beta-, and gamma- catenins and p120) in colorectal polyps

Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: Rationale for future randomised trials in human papilloma virus-negative disease

A phase I, open-label study (EGF 100262) of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)

The role of induction chemotherapy in the treatment of patients with locally advanced head and neck cancers: A review

A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma

1093 Low or undetectable levels of MPL (thrombopoietin receptor gene) mRNA expression on tumour cell lines and primary tumours compared with EPOR, ERBB2, and IGF1R

A double blind randomized phase 2 PILOT study of ERYASPASE in patients with acute lymphoblastic leukemia/lymphoma

Adhesion molecules: opportunities for modulation and a paradigm for novel therapeutic approaches in cancer

TRYbeCA-2: A randomized phase II/III study of eryaspase in combination with gemcitabine and carboplatin chemotherapy versus chemotherapy alone as first-line treatment in patients with metastatic or locally recurrent triple-negative breast cancer

381TiPTRYbeCA-2: A randomized phase II/III study of eryaspase in combination with gemcitabine and carboplatin chemotherapy versus chemotherapy alone as first-line treatment in patients with metastatic or locally recurrent triple-negative breast cancer

381TiP - TRYbeCA-2: A randomized phase II/III study of eryaspase in combination with gemcitabine and carboplatin chemotherapy versus chemotherapy alone as first-line treatment in patients with metastatic or locally recurrent triple-negative breast cancer

P-098TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441)

P-80 TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma

201PEXPLORATORY ANALYSIS OF CIRCULATING FREE DNA TO IDENTIFY BIOMARKERS PREDICTIVE OF OUTCOME IN GALAXY-1, A LARGE RANDOMIZED PHASE IIB STUDY OF GANETESPIB IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL ALONE IN ADVANCED NSCLC (NCT01348126)

Exploratory Analysis of Circulating Free Dna to Identify Biomarkers Predictive of Outcome in Galaxy-1, a Large Randomized Phase Iib Study of Ganetespib in Combination with Docetaxel Versus Docetaxel Alone in Advanced Nsclc (Nct01348126)

Phosphorylation of beta-catenin and epidermal growth factor receptor by intestinal trefoil factor

FGF‐1 and FGF‐2 regulate the expression of E‐cadherin and catenins in pancreatic adenocarcinoma

A Phase 2b of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180)

Abstract PD5-3: Anti-metastatic activity, chemotherapeutic enhancement and therapeutic potential of targeting Hsp90 with ganetespib in triple negative breast cancer

Suchergebnisse filtern